Quark Pharmaceuticals says the FDA has approved its IND application for DGFi, an experimental siRNA drug for kidney transplant patients. "We are pleased with the FDA acceptance of our DGFi IND ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback